Comments on: No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas

Comments on: No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/rituximab-and-upfront-autologous-hematopoietic-stem-cell-transplantation-for-non-hodgkin-lymphomas/ Thu, 19 Sep 2019 16:26:33 +0000 hourly 1 https://wordpress.org/?v=6.4.3